Catecholamines facilitate VEGF-dependent angiogenesis via β2-adrenoceptor-induced Epac1 and PKA activation by Garg, Jaspal et al.
  
 University of Groningen
Catecholamines facilitate VEGF-dependent angiogenesis via β2-adrenoceptor-induced Epac1
and PKA activation






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Garg, J., Feng, Y-X., Jansen, S. R., Friedrich, J., Lezoualc'h, F., Schmidt, M., & Wieland, T. (2017).
Catecholamines facilitate VEGF-dependent angiogenesis via β2-adrenoceptor-induced Epac1 and PKA
activation. Oncotarget, 8, 44732-44748. https://doi.org/10.18632/oncotarget.17267
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Oncotarget1www.impactjournals.com/oncotarget
Catecholamines facilitate VEGF-dependent angiogenesis via β2-
adrenoceptor-induced Epac1 and PKA activation
Jaspal Garg1, Yu-Xi Feng1, Sepp R. Jansen1, Julian Friedrich2, Frank Lezoualc'h3, 
Martina Schmidt4, Thomas Wieland1
1Institute of Experimental and Clinical Pharmacology and Toxicology, Medical Faculty Mannheim, Heidelberg University, 
Mannheim, Germany
25th Medical Clinic, University Hospital Mannheim, Heidelberg University, Mannheim, Germany
3Institute of Cardiovascular and Metabolic Diseases, Inserm UMR-1048, Université Toulouse -Paul Sabatier, Toulouse, France
4Center of Pharmacy, Department of Molecular Pharmacology, University of Groningen, Groningen, The Netherlands
Correspondence to: Thomas Wieland, email: thomas.wieland@medma.uni-heidelberg.de
Keywords: angiongenesis, cAMP, VEGF, EPAC, PKA
Received: March 24, 2017    Accepted: March 30, 2017    Published: April 20, 2017
ABSTRACT
Chronic stress has been associated with the progression of cancer and 
antagonists for β-adrenoceptors (βAR) are regarded as therapeutic option. As they 
are also used to treat hemangiomas as well as retinopathy of prematurity, a role 
of endothelial β2AR in angiogenesis can be envisioned. We therefore investigated 
the role of β2AR-induced cAMP formation by analyzing the role of the cAMP effector 
molecules exchange factor directly activated by cAMP 1 (Epac1) and protein kinase 
A (PKA) in endothelial cells (EC). Epac1-deficient mice showed a reduced amount of 
pre-retinal neovascularizations in the model of oxygen-induced retinopathy, which is 
predominantly driven by vascular endothelial growth factor (VEGF). siRNA-mediated 
knockdown of Epac1 in human umbilical vein EC (HUVEC) decreased angiogenic 
sprouting by lowering the expression of the endothelial VEGF-receptor-2 (VEGFR-2). 
Conversely, Epac1 activation by β2AR stimulation or the Epac-selective activator 
cAMP analog 8-p-CPT-2’-O-Me-cAMP (8-pCPT) increased VEGFR-2 levels and VEGF-
dependent sprouting. Similar to Epac1 knockdown, depletion of the monomeric GTPase 
Rac1 decreased VEGFR-2 expression. As Epac1 stimulation induces Rac1 activation, 
Epac1 might regulate VEGFR-2 expression through Rac1. In addition, we found that 
PKA was also involved in the regulation of angiogenesis in EC since the adenylyl 
cyclase (AC) activator forskolin (Fsk), but not 8-pCPT, increased sprouting in Epac1-
depleted HUVEC and this increase was sensitive to a selective synthetic peptide PKA 
inhibitor. In accordance, β2AR- and AC-activation, but not Epac1 stimulation increased 
VEGF secretion in HUVEC.
Our data indicate that high levels of catecholamines, which occur during chronic 
stress, prime the endothelium for angiogenesis through a β2AR-mediated increase in 
endothelial VEGFR-2 expression and VEGF secretion.
INTRODUCTION
Angiogenesis is a complex process which includes 
migration and proliferation of endothelial cells (EC), 
establishment of a novel basement membrane and 
recruitment of peri-endothelial cells to the walls of the new 
vessels formed from pre-existing ones [1]. Pathological 
angiogenesis occurs in numerous diseases and is regulated 
by angiogenic factors and their receptors. Especially, the 
vascular endothelial growth factor (VEGF) – VEGF-
receptor-2 (VEGFR-2) signaling cascade has been studied 
in detail. Its importance in pathological angiogenesis has 
been verified and this cascade is therapeutically targeted, 
for example in tumor angiogenesis [2].
Chronic stress, which results in high levels of 
circulating catecholamines, has been linked to the 
progression of cancer and to support tumor angiogenesis 
[3, 4]. G protein-coupled receptors (GPCRs) also 
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contribute to the regulation of angiogenesis in EC [5–7]. 
Nevertheless, the β2- adrenergic receptor (β2AR) which 
is the main isoform of endothelial β-adrenoceptors 
and induces cAMP production, has been linked to the 
lowering of endothelial permeability [8, 9]. Recent 
evidence from pre-clinical and clinical observations, 
indicate that β2AR- selective antagonists as well as non-
subtype selective antagonists can ameliorate pathological 
angiogenesis in infantile hemangiomas and proliferative 
retinopathy [10–14]. Mechanistically, it was proposed 
that β2AR-antagonism counteracts the catecholamine - 
β2AR – cAMP – protein kinase A (PKA) driven VEGF 
production in several cell types including EC, especially 
under hypoxic conditions [10]. Besides the activation of 
PKA, cAMP activates another signaling pathway which 
is dependent on the exchange factor directly activated 
by cAMP (Epac). Epac proteins, Epac1 and Epac2, are 
guanine nucleotide exchange factors for the monomeric 
GTPase Rap. Epac1 is expressed in EC and its activation 
contributes to the above mentioned cAMP-dependent 
increase in endothelial tightness [15, 16]. Whether and 
how it contributes to the regulation of angiogenesis is still 
a matter of debate. Whereas one in vitro study reports its 
involvement in pro-angiogenic signaling [17], two other 
reports indicate involvement in anti-angiogenic pathways 
[18, 19].
We therefore investigated whether Epac1 is of 
importance for the β2AR- antagonist sensitive, oxygen-
induced retinopathy (OIR) in mice [13], and analyzed 
the role of Epac1 as additional mediator of cAMP effects 
in angiogenic signaling in cultured EC. We provide 
evidence that Epac1 is regulating the expression and the 
amount of endothelial VEGFR-2 in a cAMP-dependent 
manner. In addition, we show that, together with the 
cAMP-PKA induced VEGF expression and secretion, 
the β2AR-cAMP-Epac1-dependent up-regulation of 
the VEGFR-2 is conditioning the endothelium for 
angiogenesis.
RESULTS
Epac1 deficient mice are less susceptible to 
oxygen-induced angiogenesis
In contrast to humans, which complete the 
maturation of the retinal vasculature at the time of 
birth, the vascular network in the mouse retina starts 
its development immediately after birth and reaches 
its mature state after three weeks of age. Therefore, 
the mouse retina is often used to study physiological 
angiogenesis in mammals. In addition, by subjecting 
the pups to the well-characterized OIR model [20, 
21], also pathological angiogenesis, occurring for 
example in patients with diabetic retinopathy or 
human preterm infants suffering from retinopathy of 
prematurity [22], can be studied. Thus, to investigate 
whether Epac1 contributes to the regulation of vessel 
outgrowth in the retina, we analyzed physiological and 
pathological angiogenesis in Epac1-deficient (Epac1-/-) 
mice and control littermates [23]. Similar to control 
animals, Epac1-/- mice displayed a normally developed 
retinal vasculature at postnatal day 5 (p5) and p17 
(Supplementary Figure 1A-1B). Also, the morphology 
of the retinal arterioles was unchanged (Supplementary 
Figure 1B). Therefore, the data indicate no obvious role 
of Epac1 in the physiological angiogenesis and vessel 
development in the mouse retina. Since in the OIR 
model, the contribution of the β2AR to pathological 
angiogenesis has already been established [13, 24], we 
next subjected WT and Epac1-/- mice to the OIR model. 
Consistent with previous studies [25], about 40 pre-
retinal neovascularizations/section occurred in the retina 
of WT mice (Figure 1). In contrast, the number of pre-
retinal neovascularizations was significantly reduced 
in Epac1-/- mice (Figure 1A), despite the existence of 
similar levels of hypoxia in both groups (as judged by the 
formation of avascular zones, Figure 1B). These results 
therefore indicate an important contribution of Epac1 to 
the pathological, but not physiological angiogenesis in 
the mouse retina.
Epac1 is involved in the regulation of angiogenic 
responses in HUVEC
Epac1-/- mice used in this study are deficient 
for Epac1 in all cell types. Therefore, phenotypic 
alterations observed in the retina of Epac1-/- mice might 
originate from several retinal cell types. Nevertheless, 
the pathological angiogenesis in the OIR model is 
driven by VEGF and VEGFR-2 activation on EC [21]. 
Therefore, we studied the effect of an acute, siRNA 
(siEpac1-1) – mediated depletion of Epac1 in EC on 
spheroid sprouting angiogenesis in HUVEC, a well-
established model to investigate the effects of pro- and 
antiangiogenic factors in vitro. As shown in Figure 
2A-2B, an about 90% depletion of Epac1 significantly 
impaired basal and VEGF-induced sprouting indicating 
an involvement of Epac1 in the regulation of 
angiogenesis in EC. As a control for the specificity of 
the siRNA-mediated depletion, we used a second Epac1-
specific siRNA (siEpac1-2) and studied sheet migration 
in the classical wound-healing assay as well as sprouting 
of HUVEC. The efficacy of siEpac1-2 to reduce Epac1 
expression was similar to siEpac1-1 (Figure 2C) and 
Epac1 depletion by this siRNA significantly inhibited 
VEGF-induced sheet migration (Figure 2D) and basal as 
well as VEGF-induced sprouting (see Figure 7A).
To further characterize the role of Epac1 in 
sprouting angiogenesis, we treated HUVEC with an 
Epac-specific cell permeable cAMP analog, 8-p-CPT-
2’-O-Me-cAMP (8-pCPT) and the adenylyl cyclase 
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(AC) activator forskolin (Fsk). Both, Fsk- and 8-pCPT-
treatment had no influence on the Epac1 protein content 
in HUVEC (data not shown). The efficacy of these 
treatments to activate Epac1 was controlled by quantifying 
the amount of Rap1-GTP by an effector pull-down assay 
(Figure 3B, Supplementary Figure 2). The stimulation 
of HUVEC spheroids with 8-pCPT or Fsk significantly 
increased the sprouting angiogenesis (Figure 3A). 
Similarly, the activation of Epac1 by 8-pCPT significantly 
increased sheet-migration in the wound-healing assay 
(Supplementary Figure 3). Taken together, all these results 
point towards an important role of Epac1 in the regulation 
of pro-angiogenic responses in EC.
Figure 1: Retinae of Epac1-/- mice are protected from oxygen-induced vascular damage. New born pups at p7 along with 
their nursing mothers were put into 75% oxygen for 5 days and then returned to room air for another 5 days to induce relative hypoxia. 
At p17, mice were sacrificed, eyes enucleated and then fixed. (A) After embedding the eyes into paraffin, serial retinal sections were cut 
and stained with periodic acid and Schiff’s base followed by hematoxylin. Representative pictures of one such retinal section from WT 
and its littermate Epac1-/- mouse are shown. White arrowheads show the neovascular tufts. ILM: inner limiting membrane, GCL: ganglion 
cell layer, INL: inner nuclear layer. A quantification of neovascular endothelial nuclei originating from the ILM towards the vitreous per 
section per eye in WT and Epac1-/- mice is shown below (n=13, Student’s unpaired t-test, *p<0.01 vs. WT). (B) Retinae were dissected and 
subsequently stained with collagen IV antibody followed by staining with FITC-conjugated secondary antibody to visualize the retinal 
vasculature. Area of avascular zone relative to total retinal area in WT and Epac1-/- mice from (B) to compare the levels of hypoxia present 
in the retina at p17 (n=7). Scale bar in (A): 20 μm, in (B): 200 μm.
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Figure 2: siRNA-mediated depletion of Epac1 in HUVEC impairs basal and VEGF-induced angiogenic responses. (A) 
Sub-confluent HUVEC were either transfected with control siRNA or with siRNA against Epac1 (siEpac1-1). A representative Western blot 
is shown to detect the efficiency of knockdown 48 h post transfection (above). γ-tubulin was used as a loading control. Quantification of 
Epac1 bands relative to γ-tubulin using densitometric analysis is shown below (n=10, Student’s paired t-test, *p<0.001 vs. siControl). (B) 
24 h after transfection with the indicated siRNAs, sprouting assay was performed and spheroids were stimulated with or without 50 ng/ml 
of VEGF. Representative pictures are shown above. The mean of the cumulative sprout length measured from about 10 spheroids is shown 
below (n=5, Repeated measures of two-way ANOVA with Bonferroni’s multiple comparison post-test, *p<0.05 vs. Basal siControl, #p<0.05 
vs. VEGF siControl). (C) is similar to A except that a different siRNA sequence against Epac1 (siEpac1-2) (n=39, Student’s paired t-test, 
*p<0.001 vs. siControl) was used. (D) 48 h post transfection with the indicated siRNAs, a ‘scratch’ was created in HUVEC monolayer 
followed by stimulation with or without 50 ng/ml VEGF. The data show the migrated distance 24 h post stimulation (n=5, repeated 
measures of two-way ANOVA with Bonferroni’s multiple comparison post-test, *p<0.05 vs. siControl Basal, #p<0.05 vs. VEGF siControl).
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Figure 3: Activation of β
2
AR increases sprouting angiogenesis by cAMP-dependent activation of Epac1. (A) In the 
sprouting assay, HUVEC spheroids were stimulated with either 30 μM of the Epac activator (8-pCPT) or by 10 μM forskolin (Fsk) for 
24 h. Subsequently, the cumulative sprout length was measured (n=5, one-way ANOVA with Bonferroni’s multiple comparison post-test, 
*p<0.05 vs. Basal, #p<0.05 vs. 8-pCPT). (B) Serum starved HUVEC were stimulated with either 30 μM 8-pCPT or 10 μM Fsk for 10 
min, followed by an active Rap1-pull down assay. Subsequently, total and GTP-bound Rap1 were detected using Western blot analysis. A 
representative blot is shown in the above panel. For the quantification of the Rap1-GTP bands relative to total Rap1, densitometric analyses 
from the Western blots were performed (n=3, one-way ANOVA with Bonferroni’s multiple comparison post-test, *p<0.05 vs. Basal). (C) 
After 20 min pre-treatment with 75 μM of IBMX, HUVEC were stimulated for 10 min with either 5 μM of isoproterenol (Iso) or 10 μM of 
Fsk. Cells were lysed and the cAMP content was measured by ELISA (n=5, one-way ANOVA with Bonferroni’s multiple comparison test 
*p<0.05 vs. Basal, #p<0.05 vs. Iso). (D) An active Rap1-pull down assay was performed as in B, after 10 min stimulation with 5 μM Iso. A 
representative blot and the quantification are shown (n=5, Student’s paired t-test *p<0.05 vs. Basal). (E) Shows the effect of 5 μM Iso on the 
cumulative sprout length in the presence or absence of 10 μM atenolol (n=4-8, one-way ANOVA with Bonferroni’s multiple comparison 
test, *p<0.05 vs. Basal without atenolol). (F) Shows the effect of 10 μM salbutamol on the cumulative sprout length (n=4, Student’s paired 
t-test *p<0.05 vs. Basal).
Oncotarget6www.impactjournals.com/oncotarget
Stimulation of the β
2
-adrenoceptor increases 
sprouting angiogenesis in HUVEC
HUVEC, like other EC, express various Gs 
protein coupled receptors (GsPCRs) including βARs, 
predominantly of the β2 subtype [8], which upon agonist 
binding induce cAMP production and thus Epac1 
activation [26]. We therefore stimulated HUVEC with the 
βAR agonist isoproterenol (Iso). As shown in Figure 3C-
3D, Iso treatment indeed significantly increased cAMP 
levels and induced Epac1 activation (as determined by 
active Rap1 pull-down) in HUVEC. Similar to direct 
Epac1 activation, the treatment of HUVEC spheroids 
with Iso significantly increased sprouting angiogenesis 
(Figure 3E). As this increase was not sensitive to the 
β1AR antagonist atenolol, but was mimicked by the β2AR-
specific agonist salbutamol (Figure 3F), we conclude 
that the β2AR is specifically involved in the regulation of 
angiogenic sprouting.
Activation of PKA contributes to the cAMP-
induced increase in sprouting angiogenesis by 
increasing VEGF expression and secretion
As shown in Figure 3A, Fsk was more effective than 
8-pCPT in increasing sprouting angiogenesis, although 
Epac1 activation by Fsk was weaker than by 8-pCPT 
(Figure 3B). As these data point towards a role of PKA in 
the cAMP-dependent regulation of sprouting in HUVEC, 
we compared the effect of Fsk and 8-pCPT on angiogenic 
sprouting with and without Epac1 depletion. As expected, 
8-pCPT, which selectively activates Epac, was unable to 
increase sprouting in Epac1-depleted HUVEC. However, 
Fsk still increased sprout formation significantly in Epac1-
depleted cells, suggesting the involvement of an additional 
non-Epac1 cAMP-effector, most likely PKA (Figure 
4A). Accordingly, treatment of HUVEC with a selective 
myristoylated-PKA inhibitor peptide (PKI) significantly 
lowered Fsk-induced sprouting angiogenesis (Figure 4B). 
The Epac1-dependent sprouting in response to 8-pCPT 
was not attenuated by PKI, validating the specificity 
of this inhibitor as wells as of 8-pCPT in the spheroid 
based sprouting assay (Figure 4C). In line with these 
data, which show an involvement of PKA, a significant, 
Iso-induced  increase in sprouting was still detectable in 
Epac1-depleted HUVEC although the Iso-stimulated Rap1 
activation was completely suppressed (Supplementary 
Figure 4).
Secretion of VEGF is known to increase 
angiogenic sprouting in EC in an autocrine manner [27]. 
Moreover, a cAMP- and PKA-dependent induction of 
VEGF synthesis has been reported from a variety of cell 
types including HUVEC [28]. Therefore, we assessed 
the effect of Epac and PKA activation on the expression 
of VEGF by quantifying the VEGF mRNA in HUVEC. 
Interestingly, Fsk but not 8-pCPT increased the VEGF 
mRNA content indicating that PKA, but not Epac1, is 
involved in the regulation of VEGF transcription (Figure 
4D). In line, Fsk and Iso, but not 8-pCPT significantly 
increased VEGF in the culture medium (Figure 4E). 
Taken together, these results demonstrate that besides 
Epac1, PKA activation contributes to cAMP-induced 
sprouting angiogenesis by enhanced production and 
secretion of VEGF.
Epac1 and Rac1 activity similarly regulate 
VEGFR-2 expression
In line with the inability of 8-pCPT to increase 
VEGF expression, its mRNA content (Supplementary 
Figure 5) and secretion (Figure 5) were also unaffected by 
the depletion of Epac1 in HUVEC. We thus investigated 
whether Epac1 influences the amount of VEGFR-2, 
which mediates VEGF effects on endothelial cells 
[29]. Interestingly, the VEGFR-2 mRNA content was 
significantly reduced by about 50% in Epac1 depleted 
cells (Figure 5B). In line, the VEGFR-2 protein amount 
in HUVEC was also reduced by about 35% in Epac1 
depleted cells (Figure 5A). Similar to HUVEC, the 
siRNA-mediated depletion of Epac1 in bovine aortic 
endothelial cells also decreased the VEGFR-2 levels and 
hence sprouting (Supplementary Figure 6). Furthermore, 
according to data base searches (TargetScan, RefGene), 
transcription of the Epac1 encoding gene rapgef3 can 
be targeted by microRNA-92b (miR-92b). We therefore 
overexpressed this microRNA in HUVEC (Figure 5D) 
and analyzed the protein levels of Epac1 and VEGFR-2. 
The overexpression of miR-92b not only reduced Epac1 
content by 55%, but also lowered the VEGFR-2 amount 
by 42%, indicating that a decrease in protein content of 
Epac1 by any approach (siRNA or miRNA), diminishes 
VEGFR-2 levels. We next studied whether the activation 
of Epac1 increases the VEGFR-2 protein levels. As shown 
in Figure 5E, treatment of HUVEC with 8-pCPT for 24 h 
significantly up-regulated the VEGFR-2 amount by about 
40%. Interestingly, treatment with maximally stimulating 
concentrations of Fsk or Iso increased the VEGFR-2 
protein level to a similar extent suggesting a role of 
Epac1, but not of PKA, in the up-regulation of VEGFR-2 
expression.
The monomeric GTPase Rac1 contributes to VEGF-
induced EC migration by formation of lamellipodia and 
membrane ruffles [30]. In addition, it has been shown 
that Rac1 regulates VEGFR-2 expression in EC [31]. In 
accordance with data in the literature [15, 32], the selective 
activation of Epac1 increased the GTP-loading on Rac1 
(Figure 6A) in an Epac-dependent manner (Supplementary 
Figure 7). We therefore tested, whether Rac1 knockdown 
decreases VEGFR-2 mRNA and protein levels in HUVEC 
to a similar extent as Epac1 depletion. As shown in Figure 
6B, transfection of HUVEC with a validated Rac1-specific 
siRNA decreased Rac1 protein level by about 50% without 
Oncotarget7www.impactjournals.com/oncotarget
any effect on Epac1 expression. Nevertheless, the decrease 
in Rac1 expression was accompanied by a significant loss 
of VEGFR-2 protein and mRNA by about 30% and 36%, 
respectively (Figure 6B-6C). Interestingly, the depletion 
of Rac1 affected neither VEGF transcription (data not 
shown) nor its secretion (Figure 6D). Taken together, these 
data indicate that the regulation of VEGFR-2 expression 
by Epac1 correlates with Rac1 activity in EC.
Regulation of the VEGFR-2 expression by 
Epac1 influences sprouting angiogenesis even 
in the presence of maximally stimulating 
concentrations of VEGF
To address the question whether the alterations 
in VEGFR-2 protein levels are functionally relevant 
even at saturating concentrations of VEGF, we analyzed 
basal and VEGF-stimulated (50 ng/ml) sprouting with 
and without Epac1 depletion (Figure 7A) or stimulation 
with 8-pCPT and Fsk (Figure 7B). Importantly, Epac1 
depletion significantly decreased VEGF-induced 
sprouting angiogenesis. In accordance, the stimulation 
of Epac1 activity further enhanced the maximal VEGF-
induced sprouting angiogenesis significantly. In contrast 
to the basal condition, there was however no significant 
difference in the effects of 8-pCPT and Fsk on the 
maximally VEGF-induced response which shows that 
the PKA-induced VEGF secretion is functionally 
irrelevant under this specific condition. Taken together, 
the data therefore indicate that the observed alterations in 
VEGFR-2 expression are of functional relevance even if 
high VEGF concentrations, originating for example from 
hypoxic conditions in a tumor, are present.
Figure 4: PKA contributes to cAMP-induced increase in sprouting angiogenesis. (A) 24 h after transfecting HUVEC with 
either control siRNA or siRNA against Epac1, sprouting assays were performed in the presence or absence of either 30 μM of the Epac 
activator (8-pCPT) or 10 μM forskolin (Fsk). Subsequently, the cumulative sprout length was measured (n=10, repeated measures of two-
way ANOVA with Bonferroni’s multiple comparison post-test; *p<0.05 vs. siControl Basal, §p<0.05 vs. siControl 8-pCPT, #p<0.05 vs. 
siEpac1 Basal). (B) In the sprouting assay, HUVEC spheroids were pre-treated with or without 1 μM of myristoylated-PKI (PKI) for 20 
min followed by stimulation with or without 10 μM Fsk for 24 h. The cumulative sprout length was analyzed subsequently (n=4, two-way 
ANOVA with Bonferroni’s multiple comparison test, *p<0.001 vs. Control Basal, #p<0.05 vs. Fsk Control). (C) In the sprouting assay, 
after 20 min of pre-treatment with or without 1 μM of PKI, spheroids were stimulated with 30 μM 8-pCPT (n=5, one-way ANOVA with 
Bonferroni’s multiple comparison test, *p<0.05 vs. Basal). (D) Serum starved HUVEC were stimulated with either 30 μM of 8-pCPT or 10 
μM of Fsk. 8h post stimulation, the amount of VEGF mRNA was quantified relative to RPL10 mRNA by qPCR (n=6, one-way ANOVA 
with Bonferroni’s multiple comparison test, *p<0.05 vs. Basal, #p<0.05 vs. 8-pCPT (E) Serum starved HUVEC were stimulated with either 
30 μM 8-pCPT, 10 μM Fsk or 5 μM Iso for 24 h. Amount of VEGF secreted in the media was then measured from the supernatants using 
ELISA (n=6, one-way ANOVA with Bonferroni’s multiple comparison post-test, *p<0.05 vs. Basal).
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Figure 5: Epac1 regulates VEGFR-2 expression. (A) HUVEC were transfected with control siRNA or siRNA against Epac1. 72 h 
post transfection, cells were lysed and VEGFR-2 and Epac1 protein levels were detected using Western blot analysis. γ-tubulin was used as 
a loading control (above). Densitometric analysis for the quantification of VEGFR-2 expression relative to γ-tubulin is shown below (n=6, 
Student’s paired t-test, *p<0.01 vs. siControl). (B) 48 h post transfection with siRNAs, VEGFR-2 mRNA was quantified relative to RPL10 
mRNA (n=4, Student’s paired t-test, *p<0.05 vs. siControl). (C) After transfecting HUVEC either with control siRNA or siRNA against 
Epac1 for 48 h, the content of VEGF secreted in the media was determined using ELISA (n=3, Student’s paired t-test). (D) HUVEC were 
transfected with control pre-miRNA or with pre-miRNA 92b. 48 h post transfection, cells were lysed and miRNA-92b levels were detected 
relative to U6 miRNA by qPCR to determine the efficiency of transfection (left). Right panel shows the Western blot analysis to detect 
Epac1 and VEGFR-2 protein levels. γ-tubulin was used as loading control (n=5, Student’s paired t-test, *p<0.05 vs. miControl) (E) Serum 
starved HUVEC were stimulated for 24 h with either 30 μM 8-pCPT or 10 μM forskolin (Fsk) or 5 μM isoproterenol (Iso). Cells were 
lysed and Western blot analysis was performed to determine VEGFR-2 protein levels using anti-VEGFR-2 antibody. γ-tubulin was used as 
a house keeping protein. A representative blot is shown above. Densitometric analysis for the quantification of VEGFR-2 bands relative to 
γ-tubulin is shown below (n=7, one-way ANOVA with Bonferroni’s multiple comparison post-test, *p<0.05 vs. Basal).
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Figure 6: Rac1 as a mediator of Epac1-dependent VEGFR-2 expression. (A) Serum starved HUVEC were stimulated with 30 
μM 8-pCPT for 10 min. Subsequently, an active Rac1 pull-down assay was performed followed by Western blot analysis to detect GTP-
bound and total Rac1. A representative blot is shown above. Densitometric analyses to quantify GTP-Rac1 band relative to total Rac1 are 
shown below (n=9, Student’s paired t-test, *p<0.01 vs. Basal). (B) HUVEC were transfected with siControl or siRac1. 72 h post transfection, 
cell lysates were investigated for Rac1, VEGFR-2 and Epac1 proteins by Western blot analysis. γ-tubulin was used as a loading control. 
A representative blot is shown above. The protein content of Rac1, VEGFR-2 and Epac1 relative to γ-tubulin analysis was quantified by 
densitometry (n=4, Student’s paired t-test, *p<0.05 vs. siControl, ns, p>0.05 vs. siControl). (C) HUVEC were transfected with either control 
siRNA or siRNA against Rac1. 48 h after transfection, cell lysates were analyzed for VEGFR-2 mRNA levels by qPCR. RPL10 mRNA was 
used as an endogenous control (n=4, Student’s paired t-test, *p<0.05 vs. siControl) (D) 72 h after transfecting HUVEC with the indicated 
siRNAs, VEGF concentrations in the culture media were measured by ELISA (n=4, Student’s paired t-test, ns, p>0.05 vs. siControl).
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Figure 7: The Epac1-induced upregulation of VEGFR-2 is functionally relevant. (A) 24 h after transfection with either 
siControl or siEpac1-2, sprouting assays were performed and the resultant spheroids were stimulated with or without 50 ng/ml VEGF. The 
data show the cumulative sprout length (n=8, repeated measures of two-way ANOVA with Bonferroni’s multiple comparison post-test, 
*p<0.05 vs. Basal siControl, #p<0.05 vs. VEGF siControl). (B) Spheroids were stimulated for 24 h with either 30 μM 8-pCPT or 10 μM 
forskolin (Fsk) in the absence or presence of 50 ng/ml VEGF. The cumulative sprout length was measured subsequently (n=8, one-way 




Dual role of Epac1 in the endothelium
Epac1 is the major Epac isoform expressed in the 
endothelium and its acute activation regulates endothelial 
permeability by influencing adherence and tight junction 
formation via the activation of the monomeric GTPases 
Rap1 and Rac1 [15, 16]. Indeed, we also observed a 
significant lowering of the permeability of an HUVEC 
monolayer upon the selective Epac1 activation 
(Supplementary Figure 8). A long term activation of 
Epac1 in the endothelium might however have a different 
outcome. It is therefore not surprising that divergent results 
have been reported, indicating either a pro-angiogenic [17, 
33] or anti-angiogenic [18, 19] properties of endothelial 
Epac1, which are likely context dependent. To get an 
unbiased assessment whether Epac1 is generally involved 
in angiogenic responses, we studied physiological as well 
as pathological angiogenesis in the mouse retina. The OIR 
model was chosen because the involvement of the β2AR – 
cAMP system in the formation retinal neovascularizations 
has already been established [11, 13, 14, 24]. In line 
with the finding that the inhibition of the β2AR – cAMP 
cascade reduced the pathological angiogenesis in the 
retina by about 50% [13], Epac1 deficient mice showed a 
similar significant decrease in the occurrence of pre-retinal 
neovascularizations, indicating that Epac1 was part of the 
β2AR – cAMP cascade. In the in vitro model of cultured 
HUVEC, we obtained several lines of evidence that the 
Epac1-dependent regulation of the VEGFR-2 expression 
in EC was an important part in this response. Firstly, direct 
or indirect Epac1 activation increased VEGFR-2 levels to 
a similar extent and increased angiogenic sprouting even at 
saturating concentrations of VEGF. Secondly, depletion of 
Epac1 expression by different means (siRNA or miR92b-
induced knockdown) severely diminished VEGFR-2 
expression and hampered basal and VEGF-induced 
sprouting angiogenesis as well as sheet migration. Thirdly, 
the selective activation of Epac1 with 8-pCPT resulted 
in increased activation of the monomeric GTPase Rac1, 
the depletion of which decreased VEGFR-2 expression 
by a transcriptional mechanism [31] to a similar extent 
as Epac1 depletion. Therefore, our in vivo and in vitro 
data largely substantiate the disputed notion that Epac1, 
besides its well-known involvement in the regulation of 
endothelial barrier function, contributes to the cAMP-
dependent regulation of angiogenesis in EC.
The β
2
AR-cAMP-PKA/Epac1 cascade as a target 
in stress-conditioned angiogenesis
Chronic stress leads to constantly increased 
sympathetic tone with more circulating epinephrine and 
norepinephrine. High levels of catecholamines have been 
shown to increase VEGF production and secretion by 
activating the β2AR–cAMP–PKA pathway in a variety 
of cancer cells [3]. Therefore, chronic stress has been 
linked to the progression of cancer and especially non-
subtype specific βAR antagonists, e. g. propranolol, are 
regarded as therapeutic option [4]. Likewise propranolol 
was used to cure infantile hemangiomas [34] and to 
prevent retinopathy of prematurity [35]. Our study 
provides a feasible explanation for the effectiveness of 
these treatments. Firstly, as reported before [27], cAMP-
PKA -induced VEGF production and secretion occurs 
also in EC. Secondly, and more importantly, the cAMP-
Epac1-dependent increase in VEGFR-2 is synergistically 
amplifying the response to β2AR stimulation, and thus 
likely priming the endothelium for angiogenesis. In line 
with our data, an earlier report indicated a synergistic 
action of PKA- and Epac1-dependent exocytosis of 
Weibel-Palade bodies in EC upon β2AR stimulation [33]. 
Thus approved unspecific beta-blockers, like propranolol 
or timolol, or β2AR-specific experimental ligands 
like ICI 118,551 [13] target important mechanisms, 
PKA-driven VEGF production and Epac1-mediated 
VEGFR-2 increase, by which β2AR stimulation regulates 
angiogenesis.
Study limitations
We studied the effect of β2AR activation only 
in in vitro assays, as we could hereby ascertain that we 
can dissect the effects of cAMP-PKA and cAMP-Epac1 
activation in EC. Although this limits the significance 
of our findings on the first sight, the evidence for a 
contribution of endothelial β2AR-cAMP signaling to 
pathological angiogenesis obtained from animal models 
and from clinical studies is impressive (for review see 
[10]). Therefore, we did not perform animal experiments 
using unspecific beta-blockers or specific β2AR 
antagonists. As an endothelial specific knockout of Epac1 
is not available, we used in this study mice generally 
depleted in Epac1 [23]. Therefore, it is possible that in 
OIR model not only Epac1 depletion in EC, but also in 
other retinal cells contributed to the observed reduction in 
pre-retinal neovascularizations. Nevertheless, the similar 
effectiveness of Epac1 depletion and the inhibition of the 
β2AR [13] in the in the OIR model suggests that Epac1 
is an important mediator of β2AR stimulation in this 
response. In line with this interpretation, Epac1 depletion 
in cultured EC had a rather strong effect on VEGFR-2 
content and thus on sprouting and migration of EC.
Conclusion and future perspectives
We could show herein that increasing cAMP by 
chronic activation of β2AR in EC apparently primes the 
endothelium for angiogenesis by activation of canonical 
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PKA signaling which induces VEGF production and 
secretion as wells as an Epac1-dependent upregulation of 
VEGFR-2. Interestingly, stimulating angiogenesis in vivo 
is not unique to β2AR stimulation, but can also be achieved 
by other means of increasing endothelial cAMP, such as 
the inhibition of the cAMP degrading phosphodiesterase 
III [36] as well as a so far not well-characterized cAMP 
production inducing GPCR, i.e. GPR126 [37]. Although 
additional factors, like hepatocyte growth factor and 
angiopoietin1, might be involved in the cAMP-induced 
effects besides VEGF and VEGFR-2, these results clearly 
define the cAMP-PKA/Epac axis as molecular target 
for anti-angiogenic therapy. Exploring the therapeutic 
potential of Epac inhibitors [38, 39] in comparison to 
other options lowering the endothelial cAMP production 
is beyond the scope of this study, but can be envisioned.
The pharmacologic dissection of preclinical models 
of ovarian and prostate cancer revealed that catecholamine 
effects are mediated predominantly by β2ARs [40, 
41]. In contrast to the more prescribed β1AR-selective 
drugs, propranolol was highly active in these models of 
tumor progression. Moreover, in addition to acting on 
the endothelium the interference with similar signaling 
pathways in cancer cells, for example non-small cell lung 
carcinoma (NSCLC) cells [42, 43], might be a reason 
why NSCLC patients benefit from the incidental use of 
beta-blockers for treatment of mainly cardiovascular 
diseases [44]. A pharmaco-epidemiologic analysis of 
breast cancer progression revealed however greater 
protective effects of propranolol than β1AR-selective 
agents [45]. Therefore, from a clinical point of view, the 
use of unspecific beta-blockers, like propranolol, which 
is generally well tolerated [10], might be the best option, 
currently. Nevertheless, clinical testing of more specific 




Forskolin (Fsk), isoproterenol (Iso), atenolol, 
salbutamol, 70 kDa FITC-Dextran and 3-Isobutyl-1-
methylxanthine (IBMX) were purchased from Sigma-
Aldrich. 8-p-CPT-2’-O-Me-cAMP (8-pCPT) and ESI-09 
were from Biolog Life Sciences (Bremen, Germany). 
Recombinant human VEGF 165 was from PeproTech and 
myristyolated-PKA inhibitor peptide (PKI) from Enzo Life 
Sciences. All other reagents used were of analytical grade.
Experiments with mice
Epac1+/- mice were generated in the laboratory of 
Frank Lezoualc'h, University of Toulouse, France. Animal 
care and experiments were performed in accordance with 
the Association for Research in Vision and Ophthalmology 
(ARVO) statement and were approved by the local 
government (Regierungspräsidium Karlsruhe, Germany). 
All efforts were made to reduce the animal number as well 
as the animal suffering. Genotyping of the animals was 
performed as described previously [23].
Oxygen-induced retinopathy (OIR)
Male and female Epac1+/- mice were mated and the 
resultant new-born pups at p7, along with their nursing 
mothers, were placed into a chamber with 75% oxygen 
(PRO-OX-110, compact oxygen controller, BioSpherix) 
for 5 days to mimic hyperoxia. At p12, the mice were 
returned to room air for another 5 days to induce relative 
hypoxic conditions. New-born mice along with their 
mothers kept at room air during the entire length of the 
experimental period (p0-p17) were used as normoxic 
controls. At p17, the mice were sacrificed and the body 
weight was recorded. Eyes were then enucleated and 
analyzed for pre-retinal neovascularizations and whole 
mount retinal vessels visualizations. Only homozygous 
Epac1-/- and their wild type (WT) littermates were 
analyzed in the study.
Analysis of neovascularizations and the 
vasculature in the retinae
Quantification of neovascularizations was 
performed in the p17 eyes from the OIR model as 
described previously [46]. In brief, the eyes were fixed in 
4% formalin overnight and then embedded into paraffin. 
Thereafter, serial sections of 6 μm were cut through the 
cornea and parallel to the optic nerve. The sections were 
stained with periodic acid-Schiff’s (PAS) followed by 
hematoxylin. 10 sections around the optic nerve, with an 
interval of 12 μm, were selected and the endothelial nuclei 
originating from the inner limiting membrane towards the 
vitreous side were counted under the normal microscope 
(Carl Zeiss, 40x magnification). The mean of these 10 
counted sections represents the average neovascular 
nuclei per section per eye. No neovascular cell nuclei were 
observed in the normoxic control mice.
To study the vascular morphology in the retinae, 
eyes were fixed in 4% PFA at RT for 2 h. Thereafter, the 
retinas were dissected and washed with PBS. The retinas 
were permeabilized and blocked for 1 h in a solution 
containing 1% BSA and 0.5% Triton X-100. After few 
washes with PBS, the retinas were incubated with either 
collagen IV (BP8017, Acris, 1:200) or FITC-conjugated 
lectin (L9381, Sigma-Aldrich, 1:50) at 4 °C overnight 
to visualize the retinal vessels. In case of collagen IV, 
FITC- (F0205, DAKO, 1:20) or TRITC-conjugated 
(R0156, DAKO, 1:20) swine anti-rabbit antibodies were 
used as secondary antibodies. Images were acquired with 
microscope (Olympus IX81) and the measurements of 
Oncotarget13www.impactjournals.com/oncotarget
vascularized area (p5) and avascular zone (OIR p17) were 
performed by using Olympus Cell M software.
Culturing of human umbilical vein endothelial 
cells (HUVEC)
HUVEC were isolated from human umbilical 
cords as described previously [47]. Cells were seeded 
on gelatin coated dishes and cultured in endothelial 
cell growth medium (Promocell, C-22110) containing 
supplements (Promocell, C-39210) and 2% (v/v) fetal 
calf serum (FCS) (Promocell, C-37350). Cells were 
kept under standard cell culture conditions (37 °C, 
100% humidity, 5% CO2) and used at passage 2 to 4 for 
experiments.
Transfection with small interfering RNAs 
(siRNAs) and micro RNAs (miRNAs)
HUVECs were transfected with either control siRNA 
(1027281, Qiagen) or siRNA targeting Epac1 (siEpac1-1, 
5'-AACTCGGTGAAGCGAGAATTA-3, SI0069 
8530, Qiagen; siEpac1-2, 5’-AGGGCACTTCGT 
GGTACATTA-3’, SI00698528, Qiagen), Rac1 
(5’-ATGCATTTCCTGGAGAATATA-3’, SI02655051, 
Qiagen) at 60-70% confluency. Cells were transfected 
in 6-well plates using 250 pmol of the siRNAs per 
well. Transfection was performed according to the 
manufacturer's protocol (Lipofectamine® RNAiMAX 
Transfection Reagent, Invitrogen, 13778-150). Similarly, 
miRNAs were over-expressed by transfecting HUVEC 
with 100 pmol of either the control miRNAs (Ambion, 
AM17110) or or miRNA-92b-3p (miR-92b, Ambion, 
PM10102) using the same transfecting reagent and scale. 
48 hours after transfection, the cells were lysed in RIPA 
buffer (50 mM Tris-HCl, pH 7.4, 1% TritonX-100, 150 
mM NaCl, 1 mM EDTA, 0.1% SDS) containing 1 mM 
of DTT, 1 mM of Na3VO4 and 0.1 mg/ml of Pefabloc
®. 
Subsequently, proteins of interest were analyzed by 
Western blot analysis.
Rap1 and Rac1 GTPase activation assay
The cellular level of active Rap1 and Rac1 were 
determined using effector pulldown assays [7, 48]. Briefly, 
the serum starved HUVEC were stimulated with indicated 
reagents for indicated time. The cells were lysed in ice-
cold GST-Fish buffer (10% glycerol, 50 mM Tris–HCl, 
pH 7.4, 100 mM NaCl, 1% NP-40, 2 mM MgCl2). The 
GTP-bound small GTPases were precipitated with either 
Rap-binding domain of Ral or Rac-binding domain of 
Pak1 coupled to glutathione sepharose. The amounts of 
activated and total GTPases were then determined by 
Western blot analysis.
Western blot analysis
HUVEC were lysed in RIPA buffer (as above) and 
proteins were separated in denaturing acrylamide gels 
and subsequently transferred to nitrocellulose membranes 
(Roche). After blocking with Roti® Block (Carl Roth) for 
1 h, the membranes were probed with primary antibodies 
overnight at 4 °C followed by incubation with secondary 
antibodies. The immuno-reactive bands were visualized 
with enhanced chemiluminescence (Thermo Fischer 
Scientific) and then quantified by the densitometry 
analysis using AlphaEase FC software (Alpha Innotech). 
Following primary antibodies were used for western 
blots: anti-Epac1 (4155, Cell Signaling, 1:500), anti-
Rap1 (sc-65, Santa Cruz, 1:200), anti-Rap1a/Rap1B 
(4938, Cell Signaling, 1:1000), anti-Rac1 (610650, 
BD Biosciences, 1:1000), anti-VEGFR-2 (2479, Cell 
Signaling, 1:1000), anti-γ-tubulin (T6557, Sigma-
Aldrich, 1:5000). Following secondary antibodies were 
used for Western blot: Horseradish peroxidase conjugated 
anti-mouse (A9044, Sigma-Aldrich, 1:20,000), 
Horseradish peroxidase conjugated anti-rabbit (A9169, 
Sigma-Aldrich, 1:80,000).
Real-time PCR
Either serum starved HUVEC were stimulated 
for 8 h with the indicated substances or HUVEC were 
transfected with indicated siRNAs for 48 h. The cells 
were lysed in RLT Buffer (Qiagen), the total RNA 
was isolated (RNeasy Mini Kit, Qiagen) followed 
by synthesis of cDNA (SuperScript® VILO cDNA 
Synthesis Kit, Thermo Fischer Scientific). Real-time 
PCR was performed in triplicates by using master mix 
(KK4705, Kapa Biosystems) and the Taqman probes for 
either VEGF (Hs00900055, Invitrogen) or VEGFR-2 
(Hs00911700, Invitrogen), while RPL10 (Hs00749196, 
Invitrogen) was used as an internal control. A program 
of 50 °C x 2 min, 95 °C x 10 min followed by 40 cycles 
of 95 °C x 15 sec and 60 °C x 1 min was performed 
on Applied Biosystem’s Step-One Plus Real-time PCR 
thermocycler in a 96-well plate format. Data were 
analyzed using the ∆∆Ct method to determine the relative 
mRNA content.
VEGF measurements
Either serum starved HUVEC were stimulated 
for 24 h with the indicated substances or HUVEC were 
transfected with indicated siRNAs for 48 h. The culture 
media were then collected and immediately transferred 
to liquid nitrogen for rapid freezing and stored at - 80 
°C. VEGF concentrations were then measured by using 
a VEGF ELISA Kit (DVE00, R&D Systems, Abingdon, 
UK) following the manufacturer’s instructions.
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cAMP measurements
Serum starved HUVEC were pre-treated for 20 
min with 75 μM of IBMX to inhibit phosphodiesterase 
activity and subsequently stimulated with the indicated 
substances for 10 min. cAMP content was assessed by EIA 
Kit (BT900-066 Biotrend, Cologne, Germany) according 
to the manufacturer’s instructions.
Sprouting assay
In vitro sprouting angiogenesis assays with HUVEC 
were performed as described previously [49]. Briefly, 
400 cells were mixed with methyl cellulose and spotted 
dropwise on a culture dish, which was then incubated 
up-side down for 24 h to generate the cellular spheroids. 
Spheroids were then embedded into a 3D collagen-
based gel matrix pre-prepared from rat tail tendons 
followed by stimulation with the indicated reagents for 
24 h. The cumulative sprout length was measured by 
microscopy (Olympus IX81, 10x magnification) using 
Olympus CellM software. In an individual experiment, 
around 10 spheroids were analyzed for each condition. In 
experiments involving siRNAs, the cells were transfected 
with the indicated siRNAs, 1 day prior to the generation 
of the spheroids.
Sheet migration assay
Sheet migration assays were performed as 
previously described [50]. After overnight starvation 
of a fully confluent HUVEC monolayer, a ‘scratch’ was 
created with the help of a ‘stationery eraser’. Cells were 
washed several times to remove cellular debris and then 
were stimulated with indicated substances. Cells were 
maintained at 37 °C in a microscope stage-top incubator to 
enable time-lapse microscopy. The pictures were acquired 
every 30 min for 24 h (Olympus IX81) at two different 
locations on the edge of the scratch. The distance migrated 
was calculated by measuring the distance of the new edge 
from the starting edge from at least 10 different points by 
using the Olympus Cell M software.
Permeability assay
Endothelial permeability was assayed by monitoring 
the passage of fluorescently labeled dextran through a 
tight monolayer of HUVEC grown to confluence. Briefly, 
HUVEC were seeded on the cell culture inserts (Thincerts, 
1 μm, Greiner bio-tone). Next day, they were serum 
starved overnight followed by stimulation with 30 μM of 
8-pCPT for 20 min and subsequent addition of 2 μM of 
70 kDa dextran conjugated with on the top chamber. After 
1 h, the extent of leakage of dextran was measured in a 
multi-label plate reader (EnVision 2102, Perkin Elmer) 
by measuring the fluorescence intensity (excitation at 490 
nm, emission at 520 nm) from the lower chamber and then 
normalized to the fluorescence intensity in the respective 
upper chamber.
Statistical analyses
The statistical analyses were performed using Graph 
Pad Prism version 6. The results are reported as mean ± 
SEM and the number of experiments performed (n) is 
described in the figure legends. Data of two groups and 
more than two groups were analyzed using the Student’s 
t-test and one-way ANOVA with Bonferroni post-test, 
respectively. Data involving two or more independent 
factors were analyzed by two-way ANOVA with 
Bonferroni post-test. P values of ≤0.05 were considered 
statistically significant (*p ≤ 0.05).
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